公开(公告)号：US11981686B2

公开(公告)日：2024-05-14

申请号：US17425520

申请日：2020-01-23

Applicant: DAIICHI SANKYO COMPANY, LIMITED

Inventor： Junya Kawai ,  Osamu Iwamoto ,  Yuma Umezaki ,  Katsuyoshi Nakajima ,  Hiroyuki Tsuruoka ,  Keiji Saito ,  Nobuya Kurikawa ,  Natsumi Nishihama ,  Shinji Tanaka ,  Momoko Ogitani ,  Tomohiro Honda ,  Wataru Saitoh ,  Tsuyoshi Soneda ,  Nobuyuki Ohkawa

IPC: C07D513/18 ,  C07D513/04

CPC classification number: C07D513/18 ,  C07D513/04

Abstract: An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof,






where each symbol in Formula (1) has the same definition as that described in the specification.

公开(公告)号：US09150575B2

公开(公告)日：2015-10-06

申请号：US14566460

申请日：2014-12-10

Applicant: Daiichi Sankyo Company, Limited

Inventor： Hideki Kobayashi ,  Nobuyuki Ohkawa ,  Daisuke Takano ,  Hideki Kubota ,  Toshio Onoda ,  Toshio Kaneko ,  Masami Arai ,  Naoki Terasaka

IPC: C07D401/14 ,  A61K31/437 ,  C07D471/04

CPC classification number: C07D471/04 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4858 ,  A61K9/4875

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.

Abstract translation: 由通式（I）表示的化合物或其药理学上可接受的盐具有优异的LCAT活化作用，可用作动脉硬化，动脉硬化性心脏病，冠心病（包括心力衰竭）的治疗或预防剂中的活性成分 ，心肌梗塞，心绞痛，心脏缺血，心血管疾病和血管生成引起的再狭窄），脑血管疾病（包括中风和脑梗死），外周血管疾病（包括糖尿病血管并发症），血脂异常，低HDL-胆固醇血症或肾脏 疾病，特别是抗动脉硬化剂，其中R是任选取代的芳基或任选取代的杂芳基。

公开(公告)号：US20150152102A1

公开(公告)日：2015-06-04

申请号：US14566460

申请日：2014-12-10

Applicant: Daiichi Sankyo Company, Limited

Inventor： Hideki Kobayashi ,  Nobuyuki Ohkawa ,  Daisuke Takano ,  Hideki Kubota ,  Toshio Onoda ,  Toshio Kaneko ,  Masami Arai ,  Naoki Terasaka

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4858 ,  A61K9/4875

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.

Abstract translation: 由通式（I）表示的化合物或其药理学上可接受的盐具有优异的LCAT活化作用，可用作动脉硬化，动脉硬化性心脏病，冠心病（包括心力衰竭）的治疗或预防剂中的活性成分 ，心肌梗塞，心绞痛，心脏缺血，心血管疾病和血管生成引起的再狭窄），脑血管疾病（包括中风和脑梗死），外周血管疾病（包括糖尿病血管并发症），血脂异常，低HDL-胆固醇血症或肾脏 疾病，特别是抗动脉硬化剂，其中R是任选取代的芳基或任选取代的杂芳基。